Context of Vulnerability
Most oncology drugs
on the market today work in only a small percentage
of patients for which they are indicated and so are
associated with high treatment failure rates, typically
70-80%, with challenging side effect profiles. Because
of the relative non-selective nature of oncology drug
development, the landscape is littered with lengthy and
costly development programs and, unfortunately, high development
failure rates.
We develop patient-selective therapies by
defining the “context-of-vulnerability” for
specific tumors and therapies, allowing for treatment
of only those patients most likely to respond to specific
drugs or drug combinations.
We use a systems biology approach to discover, understand,
and exploit the vulnerabilities that arise in cells during,
and because of, the cancer process. Specific cutting edge “omics” tools,
such as high-throughput RNAi profiling supported by powerful
bioinformatics, are the core of this technology. The key
to the platform is our ability to integrate these tools
into world-class clinical development, translational drug
development, and diagnostics to help identify and select
patient populations that will be specifically responsive
to our
drugs.
Posted March 4, 2008
Copyright © 2004-2008 Cell Therapeutics, Inc., Seattle,
WA, USA. All rights reserved. "Making cancer more treatable" is
a registered mark of CTI. |
